RY 142.67 0.2741% TD 73.88 -0.8721% SHOP 90.5 -0.9088% CNR 166.11 0.2414% ENB 47.82 -0.0209% CP 108.03 0.7273% BMO 115.21 0.2088% TRI 229.53 0.0131% CNQ 46.6 0.7568% BN 56.605 0.3991% ATD 76.65 -0.1173% CSU 3771.1299 -0.0005% BNS 63.59 -0.0943% CM 65.25 0.1535% SU 50.11 0.2802% TRP 52.57 0.2288% NGT 56.35 0.1422% WCN 238.17 0.4428% MFC 35.05 0.2001% BCE 44.76 -0.1339%

Covalon Technologies Ltd.

Healthcare CA COV

2.21CAD
-0.01(0.45%)

Last update at 2024-06-18T13:30:00Z

Day Range

2.212.21
LowHigh

52 Week Range

0.962.38
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -9.25392M 0.42M -6.95222M -9.13777M 1.62M
Minority interest - - - - -
Net income -9.66321M 23.48M -6.95222M -9.13777M 1.62M
Selling general administrative 13.48M 6.72M 16.43M 26.80M 14.64M
Selling and marketing expenses - - - - -
Gross profit 7.49M 9.70M 12.49M 21.82M 19.66M
Reconciled depreciation 1.03M 0.70M 1.21M 0.63M 0.36M
Ebit -9.14233M 0.84M -7.09968M -8.24863M 1.62M
Ebitda -8.10952M 1.54M -4.88597M -7.61874M 1.97M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -9.14233M 0.84M -6.09207M -8.24863M 1.62M
Other operating expenses - - - - -
Interest expense 0.11M 0.42M 0.86M 0.89M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.11159M -0.41938M -0.86016M -0.88914M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 18.15M 19.56M 25.80M 34.00M 26.72M
Total operating expenses 27.29M 18.72M 31.89M 42.25M 25.11M
Cost of revenue 10.65M 9.86M 13.31M 12.18M 7.06M
Total other income expense net - - - -1.36216M 0.00000M
Discontinued operations -0.40930M 23.06M 0.87M 0.87M 0.87M
Net income from continuing ops -9.25392M 0.42M -6.95222M -9.13777M 1.62M
Net income applicable to common shares -9.66321M 23.48M -6.95222M -9.13777M 1.62M
Preferred stock and other adjustments - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Total assets 30.38M 40.58M 34.70M 39.61M 19.71M
Intangible assets 1.28M 0.90M 2.15M 2.36M 1.37M
Earning assets - - - - -
Other current assets - - - 0.12M -
Total liab 6.15M 7.21M 25.59M 24.68M 6.58M
Total stockholder equity 24.23M 33.37M 9.11M 14.93M 13.12M
Deferred long term liab 0.29M 0.38M 0.51M 0.61M 0.71M
Other current liab 0.21M 0.41M 0.50M 0.46M 0.21M
Common stock 43.84M 44.68M 44.61M 44.61M 39.26M
Capital stock 43.84M 44.68M 44.61M 44.61M 39.26M
Retained earnings -33.90528M -24.24207M -47.71898M -40.76675M -31.62898M
Other liab 0.05M 0.16M 0.29M 0.44M 0.13M
Good will - - 13.02M 12.92M -
Other assets 0.29M 0.51M 0.54M 0.65M 0.74M
Cash 14.06M 22.95M 3.51M 9.58M 5.48M
Cash and equivalents - - - - -
Total current liabilities 4.54M 5.00M 22.64M 17.94M 6.46M
Current deferred revenue - - - - -
Net debt - - 14.22M 8.52M -
Short term debt - - - 11.80M 1.53M
Short long term debt - - 17.72M 11.80M 1.53M
Short long term debt total - - - - -
Other stockholder equity 3.01M 1.11M 0.57M 0.37M -0.07611M
Property plant equipment 1.87M 2.11M 4.64M 1.89M 1.16M
Total current assets 27.23M 37.44M 14.85M 22.39M 17.14M
Long term investments - - - - -
Net tangible assets 23.24M 32.85M -5.55766M 0.26M 12.46M
Short term investments - - - - -
Net receivables 4.73M 6.40M 3.33M 3.64M 5.13M
Long term debt - - - 6.29M -
Inventory 4.97M 4.70M 7.20M 8.58M 5.56M
Accounts payable 3.72M 4.04M 3.90M 5.68M 4.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.14M 0.04M 0.04M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 3.15M 3.14M 19.85M 17.21M 2.57M
Capital lease obligations 2.17M 2.59M 3.18M - -
Long term debt total - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments -0.84302M -0.27853M -0.37041M -7.09569M -0.74021M
Change to liabilities -0.69242M 0.02M -1.64127M 1.29M 1.96M
Total cashflows from investing activities 0.32M 36.37M -0.37041M -7.09569M -0.74021M
Net borrowings -0.58518M -7.96614M -1.07035M 6.88M 1.52M
Total cash from financing activities -2.27120M -17.97109M -1.75277M 13.98M 2.42M
Change to operating activities -1.16968M -0.07194M -0.20344M 0.58M -0.53352M
Net income -9.66321M 23.48M -6.95222M -9.13777M 1.62M
Change in cash -8.88529M 19.44M -6.06816M 4.09M 1.33M
Begin period cash flow 22.95M 3.51M 9.58M 5.48M 4.16M
End period cash flow 14.06M 22.95M 3.51M 9.58M 5.48M
Total cash from operating activities -8.37831M 0.31M -4.02544M -2.82548M -0.60352M
Issuance of capital stock - - 0.00000M 5.50M 0.90M
Depreciation 0.92M 0.70M 0.76M 0.51M 0.25M
Other cashflows from investing activities 1.30M 36.55M -0.16436M -0.00057M -0.00012M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory -0.06337M 2.16M 1.44M -2.14411M -2.99864M
Change to account receivables 1.84M -3.19397M 0.33M 3.35M -2.31684M
Sale purchase of stock -1.72695M - - - -
Other cashflows from financing activities -0.08506M -10.01210M -0.68242M -0.40956M -0.40956M
Change to netincome 0.34M -22.78912M 2.25M 2.61M 1.32M
Capital expenditures 0.60M 0.18M 0.21M 1.26M 0.73M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.08338M -1.08121M -0.07509M 3.08M -3.89351M
Stock based compensation 0.21M 0.16M 0.94M 1.72M -
Other non cash items 0.11M 0.42M 0.86M 0.89M 1.25M
Free cash flow -9.07532M 0.44M -4.39653M -4.10906M -1.39556M

Fundamentals

  • Previous Close 2.22
  • Market Cap24.92M
  • Volume1705
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.90253M
  • Revenue TTM25.09M
  • Revenue Per Share TTM1.00
  • Gross Profit TTM 7.49M
  • Diluted EPS TTM-0.22

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COV
Covalon Technologies Ltd.
-0.01 0.45% 2.21 - - 0.99 1.18 0.69 -3.9458
NGEN
NervGen Pharma Corp
-0.02 0.86% 2.30 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc
0.02 1.20% 1.68 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc
-0.005 5.88% 0.08 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.
- -% 0.70 - - - 11.86 -163.0787

Reports Covered

Stock Research & News

Profile

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Covalon Technologies Ltd.

1660 Tech Avenue, Mississauga, ON, Canada, L4W 5S7

Key Executives

Name Title Year Born
Mr. Brian E. Pedlar Pres, CEO & Director NA
Simon Smith Chief Exec. Officer of Covalon Technologies (Europe) Ltd. NA
Gerry Arambula Pres of Covalon Technologies AG Ltd. NA
Dr. Valerio DiTizio Co-Founder, Chief Scientific Officer & VP 1968
Mr. Jason F. Gorel Interim Chief Financial Officer NA
Ms. Elaine Zhang VP of Operations NA
Mr. Ron Hebert Sr. VP of Marketing NA
Mr. Greg Leszczynski VP of HR NA
Mr. Mark Doolittle Sr. VP of Commercial Sales NA
Mr. Hamed Abbasian VP of Bus. Devel. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).